Lung Cancer Research Foundation has announced three research grant awards funded by Daiichi Sankyo and AstraZeneca

Haichuan Hu, Director of Early Clinical Development – Hematology, Oncology and Cell Therapy at Bristol Myers Squibb, recently responded to a post by Lung Cancer Research Foundation on LinkedIn:

Quoting Lung Cancer Research Foundation’s post:

“LCRF has announced three research grant awards funded by Daiichi Sankyo and AstraZeneca, totaling $810,000, focused on further developing the understanding of the proposed mechanism of action of antibody-drug conjugates (ADCs). Read more.”

Quoting Haichuan Hu’s response:

“As a previous recipient of the LCRF (Lung Cancer Research Foundation) award, I have witnessed firsthand the significant impact LCRF has made in driving important breakthroughs and innovations in lung cancer research. Their dedication to advancing innovation and improving patient care is commendable. The advent of ADCs (Antibody-Drug Conjugates) has revolutionized the landscape of cancer treatment, offering new hope and possibilities for patients. I am excited to see more enthusiasm being fostered for research and innovation in this area, as we strive to make a lasting difference in the way we can offer care to patients.”

Sources: Lung Cancer Research Foundation/LinkedIn and Haichuan Hu/LinkedIn